

IPGx PILOT Whole Genome Sequencing Extension Cohort

NCT06766071

Status RECRUITING
Sponsor Texas A&M University
Enrollment 50 participants

Key Eligibility Criteria

Inclusion (5)

- Individuals taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs.
- Ability to give and comprehend the consent process.
- Consent to donate urine samples, genetic data through buccal swabs and blood samples, and undergo a comprehensive history and physical examination.
- All genders
- Age 18-100

Exclusion (10)

- Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
 - Admitted to hospice.
 - Patient has ever been diagnosed with Hepatitis B or C.
 - Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score ≥ 10 , ALT, or AST ≥ 100 U/L or an AST/ALT ratio ≥ 2
 - Patients taking imidazole antifungal medication.
- ... and 5 more (see full listing online)

Locations (1 total)

Texas A&M Family Care, Bryan, Texas, United States

<https://clinicaltrials.gov/study/NCT06766071>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.